Plain-English translation of NCT06919393 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is collecting blood samples and medical records from adults diagnosed with acute lymphoblastic leukemia (ALL) — a serious blood cancer. Specifically, the researchers are focusing on a subtype called "triple negative" ALL, which makes up about 61% of adult ALL cases. By studying the genetic makeup of these cancers in detail, the team hopes to identify new ways to predict which patients will respond best to treatment and to develop new targeted therapies.
Although survival rates for ALL have improved dramatically over the past 40 years, many adults with triple negative ALL still have poor outcomes and lack targeted treatment options. The researchers want to better understand the genetic differences in this subtype so they can identify patients at highest risk and create new, more effective treatments tailored to their specific cancer.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will donate a blood sample and allow the research team to review your medical records and clinical data about your leukemia diagnosis and treatment. The researchers will perform genetic testing on your sample to better understand your specific cancer type. This is not an interventional trial where you receive new medication — it is a research study designed to collect information that will help improve future treatments for patients with your type of leukemia.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy
Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Enrollment target
~60 participants
Started
October 2019
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Oriana Nanni, Dr
IRST IRCCS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.